

What we've done	What we're doing now	Areas we're monitoring
<p>We updated recommendations for stratifying the risk of severe illness or death from sepsis to incorporate the National Early Warning Score (NEWS2)</p> <p>We aligned the risk stratification system in the recommendations on early non-antibiotic management sections to the NEWS2 risk strata</p> <p>We updated the recommendations on antibiotic treatment in people with suspected sepsis</p> <p>The recommendations on identifying the source of infection and involving surgical teams were broadened to cover risk of sepsis in all parts of the body and a wider range of interventions</p> <p>We have withdrawn the 2016 algorithms</p>	<p>We are reviewing the evidence in the following areas and will consider making new recommendations or updating existing recommendations on:</p> <ol style="list-style-type: none"> 1. Rapid antigen testing and rapid PCR testing for diagnosing specific infections and guiding treatment 2. Indicators of organ hypoperfusion to guide referral to critical care and administration of intravenous fluids for resuscitation 3. Intravenous fluid therapy for resuscitation in people with suspected sepsis including what volume is appropriate, how quickly IV fluids should be started and when they should be stopped 4. The clinical and cost-effective timing and route of administration of vasopressors in people with suspected sepsis 5. People who are most at risk of developing sepsis <p>We are developing new algorithms to accompany the guideline that will result from the updates listed above</p>	<p>In the future, we plan to review the use of the paediatric early warning score (PEWS) and maternity early warning score (MEWS) tools and will consider making recommendations on them in the guideline. This may include updating the recommendations on rapid antigen tests and molecular tests for sepsis, indicators of organ hypoperfusion, intravenous fluids, and vasopressors for these populations.</p> <p>Procalcitonin testing is currently covered by is covered by the NICE diagnostics guidance on procalcitonin testing for diagnosing and monitoring sepsis.</p> <p>We are monitoring ongoing trials in this area including the PRONTO trial. We will decide whether to update our recommendations on procalcitonin testing once ongoing trials in people with suspected sepsis complete.</p>